Cosmo Pharmaceuticals
Speciality pharmaceutical company that aims to become a global leader in the market of optimised therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | $25.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 7 % | 57 % | (9 %) | 188 % | (35 %) | (2 %) | 48 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 62 % | 47 % | 26 % | 64 % | 37 % | 48 % | 63 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 33 % | 17 % | (5 %) | 50 % | 29 % | 29 % | 43 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 3 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy.
Our clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases and Colon Infections.
Our effort is aimed to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection rate of pre-cancerous lesions during colonoscopy.
Along with our presence in drugs manufacturing, we have significant innovative research and operations supporting our growing portfolio of specialty products. Learn more at www.cosmopharma.com/.
Tech stack
Investments by Cosmo Pharmaceuticals
Edit